{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:58:49Z","timestamp":1781060329723,"version":"3.54.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00520-026-10780-1","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T04:36:05Z","timestamp":1779078965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mapping supportive-care evidence for febrile neutropenia prevention in breast cancer chemotherapy: a bibliometric analysis of long-acting G-CSF prophylaxis"],"prefix":"10.1007","volume":"34","author":[{"given":"Shanshan","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhui","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Dong","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"10780_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-025-01142-9","volume":"5","author":"A Tahir","year":"2025","unstructured":"Tahir A, Hassan M, Farooq A, Ashfaq S, Ayub M, Hameed I, Sheikh AZ, Ahad A, Azad J, Ahmed U et al (2025) In-hospital mortality prognostication for cancer patients with febrile neutropenia. Commun Med 5(1):460","journal-title":"Commun Med"},{"issue":"8","key":"10780_CR2","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1007\/s10147-024-02570-8","volume":"29","author":"K Nozawa","year":"2024","unstructured":"Nozawa K, Ozaki Y, Yoshinami T, Yokoe T, Nishio H, Tsuchihashi K, Ichihara E, Miura Y, Endo M, Yano S et al (2024) Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022. Int J Clin Oncol 29(8):1074\u20131080","journal-title":"Int J Clin Oncol"},{"issue":"11\u201312","key":"10780_CR3","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00508-023-02300-6","volume":"136","author":"P Gasc\u00f3n","year":"2024","unstructured":"Gasc\u00f3n P, Awada A, Karihtala P, Lorenzen S, Minichsdorfer C (2024) Optimal use of granulocyte colony-stimulating factor prophylaxis to improve survival in cancer patients receiving treatment: an expert view. Wien Klin Wochenschr 136(11\u201312):362\u2013368","journal-title":"Wien Klin Wochenschr"},{"issue":"1","key":"10780_CR4","first-page":"34","volume":"32","author":"J Glaspy","year":"2023","unstructured":"Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S (2023) Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer 32(1):34","journal-title":"Support Care Cancer"},{"key":"10780_CR5","volume":"40","author":"I Abraham","year":"2024","unstructured":"Abraham I, Crawford J, Schwartzberg L (2024) On-body injector pegfilgrastim for chemotherapy-induced neutropenia prophylaxis: current status. Cancer Treat Res Commun 40:100824","journal-title":"Cancer Treat Res Commun"},{"issue":"1","key":"10780_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12913-023-09454-z","volume":"23","author":"MA Larrarte-Gonz\u00e1lez","year":"2023","unstructured":"Larrarte-Gonz\u00e1lez MA, Pineda-Posada M, Gait\u00e1n \u00c1A, Amaya-Amaya J, Ojeda K (2023) Health professionals\u2019 preferences with the use of pegfilgrastim on-body injector at oncology centers in 8 cities in Colombia. BMC Health Serv Res 23(1):529","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"10780_CR7","volume":"31","author":"MS Aapro","year":"2023","unstructured":"Aapro MS, Chaplin S, Cornes P, Howe S, Link H, Koptelova N, Mehl A, Di Palma M, Schroader BK, Terkola R (2023) Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer. Support Care Cancer 31(10):581","journal-title":"Support Care Cancer"},{"issue":"2","key":"10780_CR8","first-page":"119","volume":"29","author":"CY Wang","year":"2023","unstructured":"Wang CY, Vouri SM, Park H, Heldermon CD, Brown JD (2023) Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: a retrospective cohort study. J Manag Care Spec Pharm 29(2):119\u2013127","journal-title":"J Manag Care Spec Pharm"},{"issue":"11","key":"10780_CR9","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1007\/s12325-023-02636-5","volume":"40","author":"H Tang","year":"2023","unstructured":"Tang H, Civoli F, Tatarewicz S, Vandenkoornhuyse N, Finck B (2023) Pharmacokinetic and pharmacodynamic bioequivalence of Pegfilgrastim-cbqv delivered via a prefilled autoinjector and prefilled syringe in healthy male participants. Adv Ther 40(11):4889\u20134906","journal-title":"Adv Ther"},{"issue":"26","key":"10780_CR10","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1200\/JCO.24.00178","volume":"42","author":"A Matikas","year":"2024","unstructured":"Matikas A, M\u00f6bus V, Greil R, Andersson A, Steger GG, Untch M, Fornander T, Malmstr\u00f6m P, Schmatloch S, Johansson H et al (2024) Tailored dose-dense versus standard adjuvant chemotherapy for high-risk early breast cancer: end-of-study results of the randomized PANTHER trial. J Clin Oncol 42(26):3077\u20133082","journal-title":"J Clin Oncol"},{"key":"10780_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101162","volume":"49","author":"A Matikas","year":"2025","unstructured":"Matikas A, Papakonstantinou A, Loibl S, Steger GG, Untch M, Johansson H, Tsiknakis N, Hellstr\u00f6m M, Greil R, M\u00f6bus V et al (2025) Benefit from dose-dense adjuvant chemotherapy for breast cancer: subgroup analyses from the randomised phase 3 PANTHER trial. Lancet Reg Health Eur 49:101162","journal-title":"Lancet Reg Health Eur"},{"issue":"1751\u20131577","key":"10780_CR12","first-page":"959","volume":"11","author":"M Aria","year":"2017","unstructured":"Aria M (2017) Informetrics CCJJo: bibliometrix\u202f: An R-tool for comprehensive science mapping analysis 11(1751\u20131577):959\u2013975","journal-title":"Informetrics CCJJo: bibliometrix : An R-tool for comprehensive science mapping analysis"},{"key":"10780_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001157","author":"JW Geng","year":"2024","unstructured":"Geng JW, Li Q, Quan WX, Lin XY, Miao YD (2024) Bibliometric analysis of worldwide research trends on tumor burden and immunotherapy: a correspondence. Int J Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000001157","journal-title":"Int J Surg"},{"issue":"1","key":"10780_CR14","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41420-023-01421-1","volume":"9","author":"YD Miao","year":"2023","unstructured":"Miao YD, Quan W, Dong X, Gan J, Ji CF, Wang JT, Zhang F (2023) A bibliometric analysis of ferroptosis, necroptosis, pyroptosis, and cuproptosis in cancer from 2012 to 2022. Cell Death Discov 9(1):129","journal-title":"Cell Death Discov"},{"issue":"2","key":"10780_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.7150\/ijbs.89376","volume":"20","author":"YD Miao","year":"2024","unstructured":"Miao YD, Quan WX, Tang XL, Shi WW, Li Q, Li RJ, Wang JT, Gan J, Dong X, Hao L et al (2024) Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers. Int J Biol Sci 20(2):621\u2013642","journal-title":"Int J Biol Sci"},{"issue":"2","key":"10780_CR16","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s11192-009-0146-3","volume":"84","author":"NJ van Eck","year":"2010","unstructured":"van Eck NJ, Waltman L (2010) Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics 84(2):523\u2013538","journal-title":"Scientometrics"},{"key":"10780_CR17","first-page":"724","volume":"2005","author":"MB Synnestvedt","year":"2005","unstructured":"Synnestvedt MB, Chen C, Holmes JH (2005) CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc 2005:724\u2013728","journal-title":"AMIA Annu Symp Proc"},{"key":"10780_CR18","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000001353","author":"YD Miao","year":"2024","unstructured":"Miao YD, Hao L, Lin SX (2024) Navigating the complex interplay between autophagy and hepatocellular carcinoma: a correspondence. Int J Surg. https:\/\/doi.org\/10.1097\/JS9.0000000000001353","journal-title":"Int J Surg"},{"key":"10780_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02938","author":"B Gyawali","year":"2026","unstructured":"Gyawali B, Bohlke K, Dickter JK, Kelkar AH, Knopf KB, Rapoport BL, Roof L, Schott S, Seshadri MR, Shilpakar R et al (2026) WBC growth factors: ASCO guideline update. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-25-02938","journal-title":"J Clin Oncol"},{"issue":"3","key":"10780_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1200\/JCO.2002.20.3.727","volume":"20","author":"FA Holmes","year":"2002","unstructured":"Holmes FA, O\u2019Shaughnessy JA, Vukelja S, Jones SE, Shogan J, Savin M, Glaspy J, Moore M, Meza L, Wiznitzer I et al (2002) Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III\/IV breast cancer. J Clin Oncol 20(3):727\u2013731","journal-title":"J Clin Oncol"},{"issue":"1","key":"10780_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdg019","volume":"14","author":"MD Green","year":"2003","unstructured":"Green MD, Koelbl H, Baselga J, Galid A, Guillem V, Gascon P, Siena S, Lalisang RI, Samonigg H, Clemens MR et al (2003) A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 14(1):29\u201335","journal-title":"Ann Oncol"},{"issue":"6","key":"10780_CR22","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR, Tjulandin SA, Barajas-Figueroa LJ, Wiens BL, Neumann TA, Schwartzberg LS (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23(6):1178\u20131184","journal-title":"J Clin Oncol"},{"issue":"19","key":"10780_CR23","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1200\/JCO.2006.06.4451","volume":"24","author":"TJ Smith","year":"2006","unstructured":"Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Balducci L, Bennett CL, Cantor SB, Crawford J, Cross SJ et al (2006) 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 24(19):3187\u20133205","journal-title":"J Clin Oncol"},{"issue":"1","key":"10780_CR24","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejca.2010.10.013","volume":"47","author":"MS Aapro","year":"2011","unstructured":"Aapro MS, Bohlius J, Cameron DA, Dal Lago L, Donnelly JP, Kearney N, Lyman GH, Pettengell R, Tjan-Heijnen VC, Walewski J et al (2011) 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer 47(1):8\u201332","journal-title":"Eur J Cancer"},{"issue":"11","key":"10780_CR25","first-page":"743","volume":"32","author":"N Scher","year":"2024","unstructured":"Scher N, Boudabous H, Partouche J, Rezaee-Vessal S, Ihout P, Rizzo C, Lamallem H, Bauduceau O, Darmon I, Bollet M et al (2024) Enhancing patient-centered care: a randomized study on G-CSF administration preferences in chemotherapy-induced neutropenia. Support Care Cancer 32(11):743","journal-title":"Support Care Cancer"},{"issue":"3","key":"10780_CR26","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s12325-023-02735-3","volume":"41","author":"H Tang","year":"2024","unstructured":"Tang H, Civoli F, Tatarewicz S, Vandenkoornhuyse N, Finck B (2024) A randomized, open-label study conducted to evaluate the bioequivalence of Pegfilgrastim-cbqv on-body injector versus prefilled syringe in healthy male participants. Adv Ther 41(3):991\u20131009","journal-title":"Adv Ther"},{"issue":"11","key":"10780_CR27","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s40261-025-01479-y","volume":"45","author":"D Ji","year":"2025","unstructured":"Ji D, Wang S, Yao W, Hou D, Wang X, Ye C, Li H, Yang H, Yi J, Lu J et al (2025) Efbemalenograstim Alfa, an Fc fusion protein, long\u2011acting granulocyte colony-stimulating factor for reducing the risk of chemotherapy-induced neutropenia: results of a Phase II randomized, multicenter, open\u2011label trial. Clin Drug Investig 45(11):889\u2013899","journal-title":"Clin Drug Investig"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-026-10780-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-026-10780-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T02:27:48Z","timestamp":1781058468000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-026-10780-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10780"],"URL":"https:\/\/doi.org\/10.1007\/s00520-026-10780-1","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"1 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Generative AI tools were used solely for language polishing, including grammatical correction and sentence structure refinement. All scientific content, data analysis, interpretation, and conclusions were verified and remain the sole responsibility of the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement on the use of generative AI tools in this manuscript"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}],"article-number":"554"}}